Literature DB >> 8635461

Functional rescue of mutant V2 vasopressin receptors causing nephrogenic diabetes insipidus by a co-expressed receptor polypeptide.

T Schoneberg1, J Yun, D Wenkert, J Wess.   

Abstract

Inactivating mutations in distinct G protein-coupled receptors (GPCRs) are currently being identified as the cause of a steadily growing number of human diseases. Based on previous studies showing that GPCRs are assembled from multiple independently stable folding units, we speculated that such mutant receptors might be functionally rescued by 'supplying' individual folding domains that are lacking or misfolded in the mutant receptors, by using a co-expression strategy. To test the feasibility of this approach, a series of nine mutant V2 vasopressin receptors known to be responsible for X-linked nephrogenic diabetes insipidus were used as model systems. These mutant receptors contained nonsense, frameshift, deletion or missense mutations in the third intracellular loop or the last two transmembrane helices. Studies with transfected COS-7 cells showed that none of these mutant receptors, in contrast to the wild-type V2 receptor, was able to bind detectable amounts of the radioligand, [3H]arginine vasopressin, or to activate the G(S)/adenylyl cyclase system. Moreover, immunological studies demonstrated that the mutant receptors were not trafficked properly to the cell surface. However, several of the nine mutant receptors regained considerable functional activity upon co-expression with a C-terminal V2 receptor peptide spanning the sequence where the various mutations occur. In many cases, the restoration of receptor activity by the co-expressed receptor peptide was accompanied by a significant increase in cell surface receptor density. These findings may lead to the design of novel strategies in the treatment of diseases caused by inactivating mutations in distinct GPCRs.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8635461      PMCID: PMC450031     

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  34 in total

Review 1.  Protein degradation in the endoplasmic reticulum.

Authors:  R D Klausner; R Sitia
Journal:  Cell       Date:  1990-08-24       Impact factor: 41.582

2.  Membrane protein folding and oligomerization: the two-stage model.

Authors:  J L Popot; D M Engelman
Journal:  Biochemistry       Date:  1990-05-01       Impact factor: 3.162

3.  Epitope tagging and protein surveillance.

Authors:  P A Kolodziej; R A Young
Journal:  Methods Enzymol       Date:  1991       Impact factor: 1.600

Review 4.  Model systems for the study of seven-transmembrane-segment receptors.

Authors:  H G Dohlman; J Thorner; M G Caron; R J Lefkowitz
Journal:  Annu Rev Biochem       Date:  1991       Impact factor: 23.643

5.  Functional heterogeneity of mutant rhodopsins responsible for autosomal dominant retinitis pigmentosa.

Authors:  C H Sung; B G Schneider; N Agarwal; D S Papermaster; J Nathans
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-01       Impact factor: 11.205

Review 6.  Structure/function relationship of proteins belonging to the family of receptors coupled to GTP-binding proteins.

Authors:  A D Strosberg
Journal:  Eur J Biochem       Date:  1991-02-26

7.  Use of eukaryotic expression technology in the functional analysis of cloned genes.

Authors:  B R Cullen
Journal:  Methods Enzymol       Date:  1987       Impact factor: 1.600

8.  Molecular cloning of the receptor for human antidiuretic hormone.

Authors:  M Birnbaumer; A Seibold; S Gilbert; M Ishido; C Barberis; A Antaramian; P Brabet; W Rosenthal
Journal:  Nature       Date:  1992-05-28       Impact factor: 49.962

Review 9.  Chimeric alpha 2-,beta 2-adrenergic receptors: delineation of domains involved in effector coupling and ligand binding specificity.

Authors:  B K Kobilka; T S Kobilka; K Daniel; J W Regan; M G Caron; R J Lefkowitz
Journal:  Science       Date:  1988-06-03       Impact factor: 47.728

10.  Antagonist binding profiles of five cloned human muscarinic receptor subtypes.

Authors:  F Dörje; J Wess; G Lambrecht; R Tacke; E Mutschler; M R Brann
Journal:  J Pharmacol Exp Ther       Date:  1991-02       Impact factor: 4.030

View more
  20 in total

Review 1.  Structural features of heterotrimeric G-protein-coupled receptors and their modulatory proteins.

Authors:  H LeVine
Journal:  Mol Neurobiol       Date:  1999-04       Impact factor: 5.590

Review 2.  Genetic variations in human G protein-coupled receptors: implications for drug therapy.

Authors:  W Sadee; E Hoeg; J Lucas; D Wang
Journal:  AAPS PharmSci       Date:  2001

3.  Evidence that prokineticin receptor 2 exists as a dimer in vivo.

Authors:  Sara Marsango; Maria Carmela Bonaccorsi di Patti; Donatella Barra; Rossella Miele
Journal:  Cell Mol Life Sci       Date:  2010-12-14       Impact factor: 9.261

Review 4.  Computational methods in drug design: modeling G protein-coupled receptor monomers, dimers, and oligomers.

Authors:  Patricia H Reggio
Journal:  AAPS J       Date:  2006-05-12       Impact factor: 4.009

5.  Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants.

Authors:  J P Morello; A Salahpour; A Laperrière; V Bernier; M F Arthus; M Lonergan; U Petäjä-Repo; S Angers; D Morin; D G Bichet; M Bouvier
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

6.  Regulation of M₃ muscarinic receptor expression and function by transmembrane protein 147.

Authors:  Erica Rosemond; Mario Rossi; Sara M McMillin; Marco Scarselli; Julie G Donaldson; Jürgen Wess
Journal:  Mol Pharmacol       Date:  2010-11-05       Impact factor: 4.436

7.  Generation and phenotype of mice harboring a nonsense mutation in the V2 vasopressin receptor gene.

Authors:  J Yun; T Schöneberg; J Liu; A Schulz; C A Ecelbarger; D Promeneur; S Nielsen; H Sheng; A Grinberg; C Deng; J Wess
Journal:  J Clin Invest       Date:  2000-12       Impact factor: 14.808

8.  Reconstitution of mutant V2 vasopressin receptors by adenovirus-mediated gene transfer. Molecular basis and clinical implication.

Authors:  T Schöneberg; V Sandig; J Wess; T Gudermann; G Schultz
Journal:  J Clin Invest       Date:  1997-09-15       Impact factor: 14.808

9.  Truncated isoforms inhibit [3H]prazosin binding and cellular trafficking of native human alpha1A-adrenoceptors.

Authors:  F Cogé; S P Guenin; A Renouard-Try; H Rique; C Ouvry; N Fabry; P Beauverger; J P Nicolas; J P Galizzi; J A Boutin; E Canet
Journal:  Biochem J       Date:  1999-10-01       Impact factor: 3.857

10.  Involvement of the V2 vasopressin receptor in adaptation to limited water supply.

Authors:  Iris Böselt; Holger Römpler; Thomas Hermsdorf; Doreen Thor; Wibke Busch; Angela Schulz; Torsten Schöneberg
Journal:  PLoS One       Date:  2009-05-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.